The DEL-1/β3 integrin axis promotes regulatory T cell responses during inflammation resolution.
Animals
Calcium-Binding Proteins
/ genetics
Cell Adhesion Molecules
/ genetics
Core Binding Factor Alpha 2 Subunit
/ genetics
Humans
Inflammation
/ genetics
Integrin beta3
/ genetics
Mice
Mice, Knockout
Signal Transduction
/ genetics
T-Lymphocytes, Regulatory
/ immunology
Transforming Growth Factor beta1
/ genetics
Transforming Growth Factor beta2
/ genetics
Adaptive immunity
Autoimmunity
Inflammation
T cells
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
received:
24
02
2020
accepted:
11
08
2020
pubmed:
21
8
2020
medline:
17
2
2021
entrez:
21
8
2020
Statut:
ppublish
Résumé
FOXP3+CD4+ regulatory T cells (Tregs) are critical for immune homeostasis and respond to local tissue cues, which control their stability and function. We explored here whether developmental endothelial locus-1 (DEL-1), which, like Tregs, increases during resolution of inflammation, promotes Treg responses. DEL-1 enhanced Treg numbers and function at barrier sites (oral and lung mucosa). The underlying mechanism was dissected using mice lacking DEL-1 or expressing a point mutant thereof, or mice with T cell-specific deletion of the transcription factor RUNX1, identified by RNA sequencing analysis of the DEL-1-induced Treg transcriptome. Specifically, through interaction with αvβ3 integrin, DEL-1 promoted induction of RUNX1-dependent FOXP3 expression and conferred stability of FOXP3 expression upon Treg restimulation in the absence of exogenous TGF-β1. Consistently, DEL-1 enhanced the demethylation of the Treg-specific demethylated region (TSDR) in the mouse Foxp3 gene and the suppressive function of sorted induced Tregs. Similarly, DEL-1 increased RUNX1 and FOXP3 expression in human conventional T cells, promoting their conversion into induced Tregs with increased TSDR demethylation, enhanced stability, and suppressive activity. We thus uncovered a DEL-1/αvβ3/RUNX1 axis that promotes Treg responses at barrier sites and offers therapeutic options for modulating inflammatory/autoimmune disorders.
Identifiants
pubmed: 32817592
pii: 137530
doi: 10.1172/JCI137530
pmc: PMC7685741
doi:
pii:
Substances chimiques
Calcium-Binding Proteins
0
Cell Adhesion Molecules
0
Core Binding Factor Alpha 2 Subunit
0
EDIL3 protein, human
0
Edil3 protein, mouse
0
ITGB3 protein, human
0
Integrin beta3
0
RUNX1 protein, human
0
Runx1 protein, mouse
0
TGFB1 protein, human
0
Tgfb2 protein, mouse
0
Transforming Growth Factor beta1
0
Transforming Growth Factor beta2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6261-6277Subventions
Organisme : NIDCR NIH HHS
ID : R37 DE026152
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS091793
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE029436
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE028561
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE024716
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE024153
Pays : United States
Références
J Clin Invest. 2017 Oct 2;127(10):3624-3639
pubmed: 28846069
Mucosal Immunol. 2008 Mar;1(2):92-5
pubmed: 19079166
Immunity. 2008 Jul 18;29(1):44-56
pubmed: 18585065
Science. 2008 Nov 14;322(5904):1101-4
pubmed: 19008446
Immunology. 2006 Oct;119(2):203-11
pubmed: 17005002
Blood. 2005 Jul 15;106(2):494-504
pubmed: 15784726
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):E2784-93
pubmed: 22988108
Nature. 2013 Dec 19;504(7480):446-50
pubmed: 24226770
Trends Immunol. 2016 Nov;37(11):803-811
pubmed: 27623114
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
J Immunol. 2004 Mar 15;172(6):3876-82
pubmed: 15004195
Nat Immunol. 2012 Oct;13(10):991-9
pubmed: 22961052
Nat Rev Immunol. 2016 Mar;16(3):149-63
pubmed: 26875830
J Immunol. 2020 Mar 1;204(5):1214-1224
pubmed: 31980574
Nat Immunol. 2009 Nov;10(11):1170-7
pubmed: 19767756
Immunol Cell Biol. 2018 May;96(5):526-535
pubmed: 29437247
Nat Immunol. 2015 Nov;16(11):1174-84
pubmed: 26414764
Trends Immunol. 2013 Jan;34(1):1-6
pubmed: 22951309
EMBO Mol Med. 2013 May;5(5):661-74
pubmed: 23592557
Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
Nat Med. 2011 Nov 20;17(12):1594-601
pubmed: 22101767
Mol Psychiatry. 2015 Jul;20(7):880-888
pubmed: 25385367
Nat Genet. 2001 Jan;27(1):20-1
pubmed: 11137993
J Immunol. 2018 Jun 15;200(12):4012-4023
pubmed: 29703862
Immunity. 2018 Oct 16;49(4):666-677.e6
pubmed: 30291029
Eur J Immunol. 2008 Jun;38(6):1654-63
pubmed: 18493985
Genome Biol. 2014;15(12):550
pubmed: 25516281
FEBS J. 2011 Jun;278(12):1980-9
pubmed: 21362139
J Immunol. 2009 May 15;182(10):6071-8
pubmed: 19414758
Immunity. 2009 Oct 16;31(4):609-20
pubmed: 19800266
Nat Immunol. 2019 Jan;20(1):40-49
pubmed: 30455459
Immunity. 2010 Sep 24;33(3):313-25
pubmed: 20870174
Blood Adv. 2017 Sep 06;1(20):1699-1711
pubmed: 29296817
Trends Mol Med. 2019 May;25(5):444-459
pubmed: 30885428
Science. 2010 Feb 26;327(5969):1098-102
pubmed: 20185720
Thromb Haemost. 2016 Apr;115(4):781-8
pubmed: 26676803
Nat Commun. 2015 Sep 16;6:8272
pubmed: 26374165
J Exp Med. 2009 Nov 23;206(12):2701-15
pubmed: 19917773
Nat Immunol. 2003 Apr;4(4):330-6
pubmed: 12612578
Nature. 2013 Dec 19;504(7480):451-5
pubmed: 24226773
Front Immunol. 2018 Mar 13;9:530
pubmed: 29593749
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Nature. 2010 Feb 11;463(7282):808-12
pubmed: 20072126
Sci Transl Med. 2015 Sep 30;7(307):307ra155
pubmed: 26424570
Immunity. 2012 Nov 16;37(5):785-99
pubmed: 23123060
J Clin Invest. 2003 Nov;112(9):1437-43
pubmed: 14597769
PLoS Biol. 2007 Feb;5(2):e38
pubmed: 17298177
J Immunol. 2007 Jun 1;178(11):6725-9
pubmed: 17513718
J Clin Invest. 2005 Nov;115(11):3276-84
pubmed: 16211090
Front Immunol. 2019 Apr 09;10:680
pubmed: 31024539
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Nat Immunol. 2012 Mar 25;13(5):465-73
pubmed: 22447028
J Clin Invest. 2009 Oct;119(10):2898-913
pubmed: 19770521
Nat Immunol. 2017 Oct;18(10):1160-1172
pubmed: 28783152
Nat Immunol. 2019 Jul;20(7):802-811
pubmed: 31213716
Front Immunol. 2018 Apr 25;9:883
pubmed: 29887862
J Leukoc Biol. 2014 Nov;96(5):809-20
pubmed: 25082151
J Exp Med. 2007 Aug 6;204(8):1945-57
pubmed: 17646406
Cell. 2015 Aug 27;162(5):1078-89
pubmed: 26317471
Nature. 2007 Apr 5;446(7136):685-9
pubmed: 17377532
Nat Commun. 2018 Feb 16;9(1):701
pubmed: 29453398
Nat Rev Immunol. 2017 Nov;17(11):703-717
pubmed: 28757603
Mucosal Immunol. 2009 Sep;2(5):403-11
pubmed: 19587639
J Immunol. 2015 Nov 15;195(10):4742-52
pubmed: 26453746
Nat Immunol. 2009 Jul;10(7):769-77
pubmed: 19483717
J Biol Chem. 2020 May 22;295(21):7261-7273
pubmed: 32280065
Nat Immunol. 2018 Jul;19(7):665-673
pubmed: 29925983
Immunity. 2018 Dec 18;49(6):1116-1131.e7
pubmed: 30446387
Immunity. 2015 May 19;42(5):903-15
pubmed: 25979421
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Thromb Haemost. 2014 May 5;111(5):1004-6
pubmed: 24352615
Annu Rev Immunol. 2009;27:485-517
pubmed: 19132915
Annu Rev Pathol. 2013 Jan 24;8:477-512
pubmed: 23157335
Front Immunol. 2018 Mar 23;9:585
pubmed: 29662491
Nat Immunol. 2007 Feb;8(2):145-53
pubmed: 17195845
Curr Opin Hematol. 2001 Jul;8(4):192-6
pubmed: 11561154
J Biol Chem. 1999 Apr 16;274(16):11101-9
pubmed: 10196194
Sci Transl Med. 2018 Oct 17;10(463):
pubmed: 30333238
Biochem Biophys Res Commun. 2014 Mar 7;445(2):369-74
pubmed: 24525119
J Autoimmun. 2015 Sep;63:23-30
pubmed: 26149776
Nature. 2015 Jul 9;523(7559):221-5
pubmed: 25924064
Cell. 2002 Nov 27;111(5):621-33
pubmed: 12464175
J Exp Med. 2012 Aug 27;209(9):1529-35
pubmed: 22908322
Genes Dev. 1998 Jan 1;12(1):21-33
pubmed: 9420328
Immunology. 2018 Feb;153(2):161-170
pubmed: 29155454
Eur J Oral Sci. 2017 Aug;125(4):258-264
pubmed: 28643381
Nat Commun. 2017 Nov 17;8(1):1600
pubmed: 29150604